Form 4: BioCardia Director Andrew Blank Acquires 111,000 Shares in Public Offering

Director Andrew Blank increased his stake in BioCardia through a recent public offering, acquiring 111,000 shares and warrants.

Summary

• On September 3, 2024, Andrew Blank, a director of BioCardia, Inc., acquired 111,000 shares of common stock through a public offering at a price of $3 per share.
• With each share purchase, Blank also received a warrant to purchase an additional share of common stock at $3.
• Following the transaction, Blank directly owns 9,812 shares and indirectly owns 134,724 shares through the Andy Blank Revocable Living Trust.
• The warrants are exercisable immediately and expire on September 3, 2029.

Sentiment

Score: 6

Explanation: Neutral sentiment. The document simply reports a transaction. The director's participation in the public offering could be seen as a positive sign, but the document itself is purely informational.

Positives

• The director's purchase of shares in a public offering could be seen as a positive signal to the market, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC to ensure transparency in insider trading activities, allowing investors to monitor the actions of company insiders.

Stakeholder Impact

• The increased ownership by a director could potentially increase investor confidence.

Key Dates

Keywords

BioCardia, Director, Andrew Blank, Public Offering, Common Stock, Warrants, Beneficial Ownership, BCDA